oa SA Pharmaceutical Journal - Clinical approach to dyslipidaemia : clinical

Volume 73, Issue 7
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



<ul> <li> Dyslipidaemia is common in general practice and is a major risk factor for atherosclerosis.</li> <li> Severe hypertriglyceridaemia (>10 mmol/l) can cause pancreatitis and may be associated with eruptive xanthomata and lipaemic serum.</li> <li> The assessment of dyslipidaemic patients should focus on the exclusion of secondary disorders, global evaluation of cardiovascular risk, lifestyle evaluation and identification of monogenic lipid disorders.</li> <li> Tendon xanthomata are always pathological and are diagnostic of a monogenic lipid disorder.</li> <li> Taking the family history is very important to identify monogenic disorders.</li> <li> Screening the family of patients with monogenic lipid disorders will reduce the incidence of premature IHD.</li> <li> Patients with monogenic lipid disorders have a very high risk for cardiovascular disease and almost all require lipid-lowering drugs.</li> <li> Patients with clinically evident vascular disease have a LDL-cholesterol target of 3 mmol/l or less.</li> <li> Patients with polygenic dyslipidaemia and no vascular disease should be given lipid-lowering drugs if their calculated risk of myocardial infarction is more than 20% in the next ten years after lifestyle modification.</li> <li> Lifestyle interventions are very effective and cheap and should be applied to all patients.</li> </ul>

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error